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Abstract
Introduction
The childhood heart disease of Friedreich’s Ataxia (FRDA) is characterized by hypertrophy
and failure. It is caused by loss of frataxin (FXN), a mitochondrial protein involved in energy
homeostasis. FRDA model hearts have increased mitochondrial protein acetylation and
impaired sirtuin 3 (SIRT3) deacetylase activity. Protein acetylation is an important regulator
of cardiac metabolism and loss of SIRT3 increases susceptibility of the heart to stress-
induced cardiac hypertrophy and ischemic injury. The underlying pathophysiology of heart
failure in FRDA is unclear. The purpose of this study was to examine in detail the physiologic
and acetylation changes of the heart that occur over time in a model of FRDA heart failure.
We predicted that increased mitochondrial protein acetylation would be associated with a
decrease in heart function in a model of FRDA.
Methods
A conditional mouse model of FRDA cardiomyopathy with ablation of FXN (FXN KO) in the
heart was compared to healthy controls at postnatal days 30, 45 and 65. We evaluated
hearts using echocardiography, cardiac catheterization, histology, protein acetylation and
expression.
Results
Acetylation was temporally progressive and paralleled evolution of heart failure in the FXN
KO model. Increased acetylation preceded detectable abnormalities in cardiac function and
progressed rapidly with age in the FXN KO mouse. Acetylation was also associated with
cardiac fibrosis, mitochondrial damage, impaired fat metabolism, and diastolic and systolic
dysfunction leading to heart failure. There was a strong inverse correlation between level of
protein acetylation and heart function.
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Conclusion
These results demonstrate a close relationship between mitochondrial protein acetylation,
physiologic dysfunction and metabolic disruption in FRDA hypertrophic cardiomyopathy and
suggest that abnormal acetylation contributes to the pathophysiology of heart disease in
FRDA. Mitochondrial protein acetylation may represent a therapeutic target for early
intervention.
Introduction
Heart disease and heart failure exert a significant morbidity and mortality burden worldwide.
Abnormal metabolism and metabolic remodeling are common pathologic features in heart
disease, such as in obesity and diabetes-related cardiomyopathy [1, 2], ischemia [3], and heart
failure [4, 5]. Mitochondrial dysfunction and heart disease are closely linked [6], and because
mitochondria are central to regulating cellular energy and fulfilling the high demands of car-
diac metabolism, it is expected that mitochondrial dysfunction plays a key pathologic role in
abnormal cardiac metabolism [7].
Mitochondrial protein acetylation is an important post-translational regulatory mechanism
of heart metabolism that has emerged in recent years. Acetylation in mitochondria is con-
trolled by the NAD+-dependent deacetylase, sirtuin 3 (SIRT3). SIRT3 responds to cellular
energy status and utilizes an “acetylation switch” to modify protein function [8] in order to
respond quickly to metabolic cues and thus, operates a chief mechanism for maintaining nor-
mal mitochondrial function and metabolism [9]. SIRT3 targets enzymes that are typically acti-
vated in response to removal of acetyl groups, and which are important to energy generation
and utilization, such as very-long-chain, long-chain, and medium-chain acyl-CoA dehydroge-
nases (VLCAD, LCAD and MCAD) [10, 11], pyruvate dehydrogenase (PDH) [12], acetyl CoA
synthetase 2 (AceCS2) [13], and electron transport chain (ETC) complexes I-III [14–16]. Addi-
tionally, SIRT3 appears to deacetylate other important proteins, such as those that provide pro-
tection from oxidative damage, e.g., superoxide dismutase 2 (SOD2) [17]. It is worth noting
here that enzyme response to acetylation state is an area of continuing investigation. For
instance, others have reported an increase in activity in LCAD in response to acetylation, spe-
cifically in obesity-related heart disease [18].
Beneficial effects of SIRT3 activity in the heart are well documented. For example, SIRT3
has been shown to protect against oxidative stress, attenuate fatty acid accumulation in the
heart [19], and prevent development of stress-induced cardiac hypertrophy [20]. Mice lacking
SIRT3 have mitochondrial dysfunction eventually resulting in myocardial energy loss, develop
hypertrophy and fibrosis in response to mechanical stress [21], and are more susceptible to the
detrimental effects of ischemia/reperfusion injury [22].
Acetylation is most exciting in the context of heart disease in that it has potential as a thera-
peutically modifiable target. For example, recent work has shown that exogenous treatment
with NAD+ precursors can increase NAD+ levels in mitochondria, activate sirtuins to reduce
protein acetylation, and improve cardiac outcome [23, 24].
The heart disease of Friedreich’s Ataxia (FRDA) results from inherited deficiency of fra-
taxin (FXN), a mitochondrial protein important in energy homeostasis. FXN is a highly con-
served mitochondrial matrix protein that functions in iron-sulfur cluster assembly, which is
integral to mitochondrial metabolic machinery [25]. Reduced expression of FXN in FRDA
results in impaired energy generation, a decreased NAD+/NADH ratio, and increased
Mitochondrial protein acetylation and heart failure
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oxidative stress [26–28]. In addition to ataxia, patients often develop hypertrophic cardiomy-
opathy and heart failure. The vast majority of patients who go on to develop cardiomyopathy
are asymptomatic until late stages of disease. The most frequent cause of mortality in FRDA
arises from cardiac etiology, most commonly due to congestive heart failure [29]. There is no
known cure.
Mice with conditional loss of FXN in the heart develop cardiac hypertrophy as early as 5
weeks of age, followed by transition to dilated cardiomyopathy and heart failure by approxi-
mately 8 weeks of age [30]. Certain biochemical and structural changes occur in the FRDA
mouse model heart as early as 4 weeks of age, including reduced activity of important meta-
bolic enzymes (such as those of the ETC complexes and aconitase) and mitochondrial ultra-
structure abnormalities [30]. The importance of these findings is that underlying changes in
the FRDA heart originate prior to overt abnormalities in cardiac function and thus, may pres-
ent a window of opportunity for intervention before irreversible changes occur.
We previously reported that mitochondrial proteins in FRDA mouse model hearts have
increased acetylation and decreased SIRT3 activity, resulting in increased acetylation of several
important metabolic enzymes, including LCAD, MCAD, AceCS2, and the ETC [28, 31]. The
reduction in SIRT3 activity is likely due to insufficient NAD+ bioavailability as a result of dys-
functional energy metabolism, and possibly by direct oxidative modification of the native
protein. The impact of abnormal acetylation in the FRDA heart has not been investigated.
Because of the important role that acetylation plays in cardiac function, we believe that loss of
SIRT3 and resultant mitochondrial protein hyper-acetylation contributes to the heart disease
of FRDA.
The purpose of the present study was to document the changes in physiology and function
that evolve over time in a model of FRDA heart failure using both non-invasive (ECHO) and
invasive left heart catheterization, and match the trajectory of cardiac pathophysiology to the
protein acetylation profile along the course of disease in order to determine the link between
acetylation of mitochondrial proteins and FRDA heart disease.
Results
Cardiac hypertrophy and diastolic dysfunction are early and persistent
findings
We used an established conditional mouse model of FRDA heart failure with absence of FXN
in the heart (FXN KO) compared to healthy littermates (FXNfl/fl) [32]. We examined cardiac
function in detail, using ECHO and invasive left heart catheterization at postnatal age day 30
±5, 45 ±4 and 65 ±5. These groups represented pre-, mid- and late heart disease according to
previous reports [30].
There were no functional or anatomic differences between hearts of FXN KO and control
mice at day 30 (Table 1).
Cardiac hypertrophy is manifest by day 45 in FXN KO animals (Table 1). Compared to
controls, day 45 FXN KO mice have thickened left ventricular (LV) posterior walls in diastole
(LVPWd) (FXN KO = 0.82 ±0.12 mm vs. FXNfl/fl = 0.64 ±0.08 mm; p<0.001), increased rela-
tive wall thickness (RWT) (FXN KO = 0.42 ±0.07 vs. FXNfl/fl = 0.33 ±0.05; p = 0.002). FXN
KO at day 45 also show findings consistent with both cardiomegaly and hypertrophy with
increased ECHO-derived LV:body (FXN KO = 5.1 ±0.9 vs. FXNfl/fl = 3.9 ±0.7; p = 0.004)
and gross heart (mg):body weight (g) ratios (FXN KO: 5.90 ±1.70 vs. FXNfl/fl: 4.41 ±0.42;
p = 0.021).
Diastolic dysfunction occurs early, is concomitant with presentation of LV hypertrophy, and
is persistent in FXN KO hearts. FXN KO mice demonstrate multiple relaxation abnormalities
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at day 45 (Fig 1, Table 1). Mitral blood flow velocity ratio of Early-to-Atrial waves (E/A) on
Doppler imaging is increased at day 45 (FXN KO = 2.4 ±0.8 vs. FXNfl/fl = 1.5 ±0.2; p = 0.003)
and 65 (FXN KO = 3.7 ±1.4 vs. FXNfl/fl= 1.4 ±0.2; p<0.001), as well as isovolumic relaxation
time (IVRT) at day 45 (FXN KO = 26.8 ±1.2 ms vs. FXNfl/fl = 23.9 ±2.3 ms; p = 0.008) and day
65 (FXN KO = 33.6 ±4.2 ms vs. FXNfl/fl = 21.9 ±2.5 ms; p<0.001). Left ventricle relaxation rate
(-dP/dt) is decreased in FXN KO compared to controls at days 45 (FXN KO = -6,087 ±1,378
mmHg/sec vs. FXNfl/fl= -9,704 ±799 mmHg/sec; p<0.001) and 65 (-4,099 ±1,104 mmHg/sec
Table 1. Heart function as measured by ECHO and invasive left heart catheterization for FXN KO and controls at ages 30, 45 and 65 days.
30 45 65
FXNfl/fl FXN KO FXNfl/fl FXN KO FXNfl/fl FXN KO
n = 7 n = 9 n = 7 n = 6 n = 7 n = 7
CATH
Age (day) 30.7 ±1.8 31.9 ±2.9 46.9 ±0.9 44.8 ±0.4** 63.6 ±3.8 64.6 ±3.4
HR (bpm) 605.3 ±85.3 577.1 ±44.6 671.4 ±95.2 580.9 ±81.4 595 ±77.1 643.3 ±105.2
EF (%) 56.0 ±9.8 49.7 ±7.4 40.9 ±11.8 48.8 ±6.7 50.2 ±6.1 25.2 ±9.5***
+dP/dt (mmHg/s) 1015 ±1848 8760 ±962 11882 ±1928 6875 ±1156*** 10809 ±1591 5165 ±1101***
-dP/dt (mmHg/s) -8114 ±1067 -7802 ±817 -9704 ±799 -6087 ±1378*** -9228 ±891 -4099 ±1104***
MaxPwr 107.5 ±31.2 84.7 ±14.5 143.3 ±32.1 67.5 ±20.7*** 121.2 ±31.5 37.3 ±14.1***
Tau (Weiss) (ms) 5.3 ±1.0 5.6 ±0.5 4.5 ±0.6 7.8 ±1.2*** 5.0 ±0.5 7.8 ±1.0***
Tau (Mirsky) (ms) 8.7 ±1.5 8.4 ±1.0 8.4 ±0.9 11.0 ± 1.3** 8.6 ± 1.0 10.9 ± 1.5**
ESP (mmHg) 88.6 ±10.2 87.4 ±9.7 103.2 ±5.4 87.7 ±11.9* 99.5 ±7.3 65.2 ±11.0***
EDP (mmHg) 11.7 ±4.5 11.0 ±3.3 10.9 ±3.8 13.0 ±5.7 8.8 ±3.0 10.0 ±5.3
ESV (μl) 22.9 ±7.9 23.1 ±5.1 26.6 ±10.7 24.8 ±5.9 26.8 ±6.9 74.7 ±15.7***
EDV (μl) 50.9 ±6.6 45.7 ±7.3 43.6 ±12.2 48.2 ±9.0 53.4 ±7.8 99.6 ±15.2***
FXNfl/fl FXN KO FXNfl/fl FXN KO FXNfl/fl FXN KO
n = 10 n = 10 n = 11 n = 10 n = 9 n = 9
ECHO
BW (g) 15.6 ±3.0 13.5 ±3.7 20.4 ±2.0 21.3 ±1.7 23.7 ±2.4 22.4 ±1.2
EF (%) 55.0 ±10.1 54.2 ±7.3 49.9 ±13.7 45.9 ±8.0 47.7 ±8.2 23.9 ±12.5***
FS (%) 28.2 ±6.4 27.6 ±5.0 25.6 ±9.2 22.7 ±4.6 23.7 ±4.9 11.1 ±6.0***
CO (ml/min) 19.7 ±7.2 18.9 ±8.1 17.4 ±5.1 16.8 ±4.6 21.4 ±4.9 13.2 ±5.1*
CI (ml/min/g) 1.2 ±0.3 1.4 ±0.4 0.87 ±0.27 0.80 ±0.24 0.89 ±0.16 0.58 ±0.23*
LVIDd (mm) 3.6 ±0.3 3.6 ±0.4 3.9 ±0.3 3.9 ±0.4 3.91 ±0.14 4.49 ±0.56**
LVPWd (mm) 0.61 ±0.12 0.58 ±0.14 0.64 ±0.08 0.82 ±0.12*** 0.62 ±0.13 0.85 ±0.22*
RWT 0.35 ±0.10 0.32 ±0.10 0.33 ±0.05 0.42 ±0.07** 0.32 ±0.07 0.39 ±0.13
LV:body 4.1 ±1.4 4.5 ±1.6 3.9 ±0.7 5.1 ±0.9** 3.47 ±0.70 5.71 ±1.19***
E/A 1.6 ±0.2 1.7 ±0.2 1.5 ±0.2 2.4 ±0.8** 1.4 ±0.2 3.7 ±1.4***
IVRT (ms) 25.1 ±3.0 23.6 ±3.4 23.9 ±2.3 26.8 ±1.2** 21.9 ±2.5 33.6 ±4.2***
Statistical significance between groups based on student’s t-test analysis:
* = p<0.05,
** = p<0.01,
***p = <0.001.
HR = heart rate; EF = ejection fraction; +dP/dt = ventricle rate of contraction; -dP/dt = ventricle rate of relaxation; maxPwr = maximum power left ventricle;
Tau (Weiss) = regression of log(pressure); Tau (Mirsky) = time required for LV pressure to fall to one-half of its value at end systolic pressure; ESP = end
systolic pressure; EDP = end diastolic pressure; ESV = end systolic volume; EDV = end diastolic volume; BW = body weight; FS = fractional shortening;
CO = cardiac output; CI = cardiac index (CO/body weight); LVIDd = left ventricular internal diameter in diastole; LVPWd = left ventricle posterior wall
thickness in diastole; RWT = relative wall thickness (2*LVPWd)/LVIDd); E/A = mitral blood flow velocity ratio of Early-to-Atrial waves; IVRT = isovolumic
relaxation time.
https://doi.org/10.1371/journal.pone.0178354.t001
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Fig 1. FXN KO mice exhibit diastolic dysfunction followed by dilated cardiomyopathy and heart failure.
(a) Representative mitral valve Doppler flow patterns (ratio of the early (E) to late (A) ventricular filling velocity, E/
A) demonstrate restrictive cardiomyopathy in FXN KO at days of age 45 and 65. (b) Echocardiographic
parasternal short axis M-mode images demonstrate progressive impairment in left ventricular wall movement
with decreased fractional shortening (FS, %) in FXN KO. (c) Parasternal short axial images illustrate the
transition to dilated cardiomyopathy with increased left ventricular internal diameter in diastole (LVIDd) in FXN
KO at day 65. (d) FXN KO pressure volume loops represent increased end-diastolic volume (EDV) at day 65
compared to controls (p<0.001) with notable rightward shift of pressure-volume curves. Values indicated in (a),
(b) and (c) are averages per group.
https://doi.org/10.1371/journal.pone.0178354.g001
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vs. FXNfl/fl= -9,228 ±891 mmHg/sec; p<0.001). Finally, Tau, the LV relaxation time constant, is
increased in FXN KO compared to controls at both day 45 (Tau Weiss: FXN KO = 7.81 ±1.22
vs. FXNfl/fl= 4.53 ±0.57 ms, p<0.001) and 65 (Tau Weiss: FXN KO = 7.81 ± 0.95 vs. FXNfl/fl=
4.99 ±0.50 ms, p<0.001), demonstrating prolonged relaxation phase in diastole.
FXN KO mice transition to dilated cardiomyopathy and heart failure
Contractility abnormalities occur in FXN KO mice as early as postnatal day 45 on invasive
measurements, with progressive decline in systolic indices on day 65 measurements (Fig 1,
Table 1). At day 45, FXN KO mice have a significant decrease in maximum ventricular power
(maxPower) compared to controls (FXN KO = 67.5 ±20.7 mWatt vs. FXNfl/fl = 143.3 ±32.1
mWatt; p<0.001) as well as rate of contraction (+dP/dt) (FXN KO = 6,875 ±1,155 mmHg/sec
vs. FXNfl/fl= 11,882 ±1,928 mmHg/sec; p<0.001). Again, at day 65, FXN KO mice demonstrate
significantly depressed contractility (+dP/dt) (5,165 ±1,100 mmHg/sec) compared to control
mice (10,809 ±1,591 mmHg/sec) (p<0.001) in addition to decreased maxPower (FXN
KO = 37.3 ± 14.1 mWatt vs. FXNfl/fl = 121.2 ± 31.5 mWatt; p<0.001).
FXN KO mice progress to overt systolic heart failure on ECHO by postnatal day 65. Com-
pared to controls, FXN KO animals have significantly reduced EF (FXN KO = 23.9 ±12.5% vs.
FXNfl/fl = 47.7 ±8.2%, p<0.001) and fractional shortening (FS) (FXN KO = 11.1 ±6.0% vs.
FXNfl/fl = 23.7 ±4.91%, p<0.001). FXN KO mice at day 65 also demonstrate reductions in both
cardiac output (CO) (FXN KO = 13.2 ±5.1 ml/min vs. FXNfl/fl = 21.4 ±4.9 ml/min, p = 0.010)
and cardiac index (CI) (FXN KO = 0.58 ±0.23 ml/min/g vs. FXNfl/fl = 0.89 ±0.16 ml/min/g,
p = 0.014) compared to controls.
Consistent with previous reports [30, 32], dilated cardiomyopathy is present in the FXN
KO at day 65. There is a significant increase in LV internal diameter in diastole (LVIDd), in
FXN KO (4.49 ±0.56 mm) compared to FXNfl/fl (3.91 ±0.14 mm)(p = 0.006), providing evi-
dence of a dilated LV. Further, the end-cycle blood volumes of the chamber in diastole are
markedly increased in FXN KO at 65 days. Left ventricle end-diastolic volume (EDV) data col-
lected with catheter-based direct volume measurements show that day 65 FXN KO mice have
an increased EDV that is almost twice that of FXNfl/fl (99.7 ±15.2 μl vs. 52.7 ±8.29 μl, respec-
tively; p<0.001), causing a dramatic rightward-shift in their pressure-volume curves (Fig 1,
Table 1).
FXN KO mice at 65 days of age maintain earlier findings of cardiomegaly on ECHO-
derived LV:body weight ratios (5.71 ±1.19) compared to FXNfl/fl mice (3.47 ±0.70) (p<0.001).
FXN KO mice at day 65 also demonstrated close to a 50% increase in gross heart:body weight
ratio (8.81 ±1.5) than that measured at day 45 (5.90 ±1.7), and significantly higher than age-
matched controls (4.70 ±0.26) (p<0.001).
Acetylation is rapidly and temporally progressive and strongly correlates
with a decline in heart function
We previously demonstrated that acetylation in the conditional FXN KO heart is dramatically
increased in late stages of heart disease and that the majority of protein acetylation was local-
ized to mitochondria [28]. Here, we examined the level of lysine acetylation in heart tissue at
each time point in which we measured cardiac function in order to determine the level of car-
diac protein lysine acetylation relative to the evolution of cardiac dysfunction from pre-disease
to overt heart failure.
We show that acetylation is modestly increased prior to onset of detectable cardiac dysfunc-
tion in the FXN KO heart at day 30. This is followed by a dramatically rapid and progressive
increase in protein acetylation compared to controls (Fig 2). We measured the expression
Mitochondrial protein acetylation and heart failure
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levels of several essential mitochondrial electron transport proteins, and as expected, based on
the established role of FXN in Fe-S cluster enzyme assembly [25, 33] and prior studies [28], the
expression of ETC complex subunits CI-NDUFA9, CII-SDBH and CIII-Rieske is reduced in
FXN KO and decreases consistently over this time course (Fig 2).
Surprisingly, when the level of acetylation was correlated with measured cardiac function,
there was a strong inverse correlation between amount of acetylation, as measured by relative
density on western blot imaging, and EF (r = -0.923) and FS (r = -0.927) (Fig 2).
Fig 2. Acetylation is increased and progresses with age in FXN KO, and correlates with worse heart function. Whole cell preparations or
mitochondrial isolates from ventricular tissue were probed for proteins of interest as indicated. (a) Acetylation of lysine residues is increased early and
progresses with age, and expression of electron transport chain complex subunits decreases in FXN KO hearts. (b) Plot of correlation between
acetylation and systolic indices of heart function shows negative correlation between level of acetylation and ventricular function. (c) FXN hearts at day
65 had significantly increased total mitochondrial protein lysine acetylation (p = 0.0339), increased acetylation of SOD2 at Lys-68 (AcK-SOD2)
(p = 0.0016), and (d) increased acetylation of LCAD compared to controls (p = 0.0291). EF = ejection fraction, FS = fractional shortening.
https://doi.org/10.1371/journal.pone.0178354.g002
Mitochondrial protein acetylation and heart failure
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To demonstrate that mitochondrial deacetylase activity is decreased or absent in the FXN
KO hearts, we probed for acetylation of known SIRT3 mitochondrial protein targets, SOD2
and LCAD. SOD2 acts to destroy superoxide radicals and is inhibited when acetylated at lysine
68. SIRT3 reverses acetylation [17, 34]. LCAD is a key enzyme in fatty acid oxidation and
reports have demonstrated increased activity in response to deacetylation by SIRT3 [35, 36].
As expected, we detected increased acetylation of both SOD2 and LCAD in the FXN KO com-
pared to controls (Fig 2), confirming decreased activity of SIRT3 deacetylase. These results are
consistent with prior studies in our lab that demonstrated hyper-acetylation of SIRT3 targets
in cardiac-specific FXN KO hearts, including AceCS2, LCAD, and MCAD [31].
Abnormal cardiac mitochondria ultrastructure is accompanied by
mitochondrial respiratory inhibition
Consistent with previous reports [30, 32], we found that pathologic changes in mitochondria
become evident on electron microscopy (EM) as early as postnatal day 30 in ventricular
tissue of FXN KO, and increase in prevalence over time (Fig 3). Mitochondrial ultrastructure
changes in FXN KO hearts include loss and collapse of cristae, disordered mitochondria-to-
sarcomere arrangement, and extensive accumulation and stacking of mitochondria, in addi-
tion to widespread electron-dense inclusions at day 65.
We quantified these observed morphological changes by measuring the ratio of myofibril-
to-mitochondria area from micrographs, and determined the percentage of abnormal mito-
chondria in each strain [37]. At day 65, the myofibril-to-mitochondria ratio was significantly
decreased in FXN KO (0.90 ± 0.46) compared to controls (1.89 ±0.47) (p = 0.011), and the
average percentage of mitochondrial area containing abnormal mitochondria in FXN KO
(78.1±26.7%) was significantly higher than in control micrographs in which no abnormalities
were detected (p = 0.002) (Fig 3).
We next examined mitochondrial respiratory function at day 65. Respiratory control ratios
(RCR) in FXN KO cardiac mitochondria (1.67 ±0.12) were significantly decreased compared
to controls (4.86 ±0.37) (p<0.001) when measured by Clark Oxygen electrodes using complex
I substrates glutamate and malate (Fig 3).
FXN KO hearts exhibit features of maladaptive ventricular remodeling
Consolidated areas of fibrotic infiltration of the heart are widespread in FXN KO mouse
hearts at day 65 (Fig 4), similar to previous reports [32]. By measuring the percent of collagen
detected in ventricular tissue on stained micrographs, we demonstrate that FXN KO mice
have more than a 1.5 times increase in fibrotic involvement of ventricular tissue compared to
controls (FXN KO = 9.1% vs. control 4.9%, p = 0.002) (Fig 4). We did not find a significant
increase in amount of collagen in the FXN KO hearts compared to controls at days 30 or 45 on
histological examination. FXN KO hearts at day 65 also display diffuse cardiomyocyte degen-
eration, indicated by the presence of vacuolation on light microscopy (Fig 4). Degenerating
cardiomyocytes were not detectable at earlier ages (data not shown).
Loss of FXN in the heart leads to cardiac steatosis and cold intolerance
Ventricular tissue of FXN KO at day 65 demonstrated a combined pattern of macro- and
microsteatosis in cardiomyocytes (Fig 5).
Because mice with loss of MCAD, or VLCAD in the heart quickly become hypothermic
when exposed to cold environment and die [38, 39], and, similarly, ablation of SIRT3 leads to
cold intolerance [36], we predicted that the conditional FXN KO would be unable to maintain
its core body temperature when exposed to a cold stress. Mice were fasted for 6 hours then
Mitochondrial protein acetylation and heart failure
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Fig 3. Abnormal cardiac mitochondria ultrastructure is accompanied by respiratory inhibition in FXN KO hearts. (a)
Representative images from electron micrographs of cardiomyocytes viewed at 11,000x. Mitochondrial ultrastructure abnormalities were
apparent in FXN KO sections and progressed from days 30 to 65. Findings included matrix density loss, mitochondrial-to-sarcomere
disarrangement, and accumulation and clumping of mitochondria. FXN KO day 65 mitochondria demonstrate cristae collapse and
dissolution, and hyperdense inclusions. Arrowhead = collapsed cristae; arrow = electron-dense intramitochondrial inclusions. (b)
Myofibril:mitochondria area ratios were significantly decreased at day 65 in FXN KO compared to controls (n = 3–8 micrographs per
strain at each age). (c) Mitochondrial functional assays demonstrated significantly decreased respiratory control ratios in FXN KO
compared to controls. There were 2–4 assay runs on pooled mitochondria from FXN KO (n = 8–12 hearts), or pooled mitochondria from
controls (n = 4–6 hearts), with 2–3 pooled hearts per run.
https://doi.org/10.1371/journal.pone.0178354.g003
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placed in a cold room at 4˚C with core body temperature monitoring every 30 minutes, for a
total period of 180 minutes. Indeed, we found that cold exposure lead to a precipitous drop in
body temperature and significantly decreased survival rate in the FXN KO animals compared
to controls (Fig 5). The majority of the FXN KO animals expired or became moribund with
body temperatures <19˚C (at which time animals were euthanized for humane reasons) prior
Fig 4. FXN KO hearts exhibit features of maladaptive ventricular remodeling. (a) Cardiac fibrosis is
progressive in the FXN KO heart. Ventricular tissue was stained using Masson’s Trichrome to detect blue-
staining fibrous tissue. (b) Percent area collagen was significantly increased in FXN KO hearts at postnatal day
65 compared to controls. (c) Evidence of cardiomyocyte degeneration in the FXN KO at day 65 is
demonstrated by vacuolation on H&E staining.
https://doi.org/10.1371/journal.pone.0178354.g004
Mitochondrial protein acetylation and heart failure
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to cessation of the three hour time period (Fig 5). Both controls and FRDA mice were observed
to be shivering with exposure to cold.
Discussion
This study is the first to document the progression of lysine-acetylated proteins and demon-
strate a correlation between acetylation and cardiac function in the heart of the conditional
FXN KO mouse model of FRDA heart disease. We have characterized the initial stages of
cardiac dysfunction and evolution to heart failure in this animal model, which mirrors that of
the FRDA human heart disease. We conclude that protein lysine acetylation increases in a tem-
porally progressive pattern and that there is a strong negative correlation between level of acet-
ylation in the heart and global heart function: as acetylation increases, ejection fraction and
fractional shortening decrease.
We found that abnormal post-translational modification of key metabolic enzymes has
occurred prior to detectable impairment in heart function in the FXN KO. Acetylation is
increased at day 30 and continues to progress over time. The first notable abnormal traits on
cardiac pathophysiology occur at 45 days of age, with thickening of the left ventricular wall
and diastolic dysfunction. As acetylation progresses, heart function continues to decline and
demonstrates features of decompensated left ventricular dilation, decreased ejection fraction
and fractional shortening, consistent with systolic heart failure. These results suggest that tar-
geting acetylation early would provide the best chance to halt or slow progression of FRDA
heart disease. Modifying acetylation only after detectable cardiac dysfunction occurs may miss
the opportunity to prevent irreversible hemodynamic changes in the FXN KO heart.
Loss of SIRT3 results in maladaptive ventricular remodeling in response to stress [19],
abnormalities in lipid metabolism, and reduced tolerance to cold exposure [36]. We found
similar outcomes in the FXN KO, which implies that loss of function of SIRT3 in the FXN KO
heart and resultant hyper-acetylation of SIRT3 target proteins plays a major role in the patho-
logic processes of FRDA mitochondrial heart disease. The absence of FXN in the heart, which
Fig 5. Loss of FXN in the heart leads to cardiac steatosis and cold intolerance. (a) FXN KO hearts demonstrate lipid accumulation in their hearts
on oil-red-O staining. (b) Mice were subjected to a 6-hour fast after which they were placed in 4˚C room for 3 hours with core body temperature
monitoring. (c) FXN KO mice were unable to maintain core body temperature upon cold exposure and suffered significantly increased cold-related
mortality rates compared to controls.
https://doi.org/10.1371/journal.pone.0178354.g005
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has an established role in manufacturing of Fe-S cluster subunits needed for enzymes vital to
oxidative metabolism, is, in and of itself, a major insult to the cardiomyocyte cellular milieu
[40]. The conditional FXN KO model thereby acts as a “stressed heart” model to examine the
role of acetylation in heart disease and failure. This is supported by our observation that
changes seen in the FXN KO are more robust, with an earlier age at onset, than those seen in
models of SIRT3 loss alone. SIRT3 activity is impaired in FRDA hearts likely due to the
decreased bioavailability of NAD+ and to oxidative damage of SIRT3 [28]. The findings in this
study can be applied to other models of heart disease and failure. Many cardiac diseases with
abnormal metabolism and energy homeostasis are liable to result in impaired SIRT3 activity in
a manner similar to the FXN KO model, leading to abnormal mitochondrial protein acetyla-
tion in the heart and impaired cardiac function. Such heart disease candidates include inher-
ited mitochondrial cardiomyopathies, diabetic and metabolic syndrome heart disease,
acquired cardiac hypertrophy, age-related and ischemic heart disease, and heart failure [18,
19]. For example, the ischemic heart results in a shift in redox state with accumulation of
NADH [41], mirroring the consequential disturbance in energy equivalents in the FRDA
heart.
More studies are needed in order to determine a causative role of abnormal acetylation in
leading to impairment of hearts with FXN loss. For instance, it would be of great interest to
determine whether normalizing the NAD+/NADH ratio in the FXN KO heart would stimulate
SIRT3 function, recover activity of targeted metabolic enzymes, and improve measured car-
diac outcome. Recent work has shown that exogenous treatment with NAD+ precursors can
increase NAD+ levels in mitochondria, reduce protein acetylation, and activate sirtuins [23,
24]. Together with our findings that mitochondrial protein acetylation impairs heart function,
this represents an attractive therapeutic potential for pharmacological modulation of protein
lysine acetylation to improve cardiac metabolism and physiologic function and prevent unre-
mitting progressive heart disease.
One limitation of this study may be that the MCK promoter used to drive Cre expression in
this model is expressed in all sarcomeric tissues, including skeletal muscle. It is not expected
that loss of FXN in skeletal muscle would significantly alter cardiac function in this study.
Indeed, in patients with FRDA, and in the original report of this mouse model [32], there is
not an identified skeletal muscle phenotype. Using the cardiac-specific alpha myosin heavy
chain promoter (α-MHC) would address this limitation. However, we determined that the
MCK promoter was the logical choice for these experiments both because the α-MHC has also
been noted to be cardio-toxic under certain conditions [42], and we wanted to avoid this con-
founding variable, and because the MCK-Cre transgene has been used extensively in our lab
and others’ to generate the FXN KO mouse [28, 32].
In conclusion, we demonstrate a close relationship between mitochondrial protein acetyla-
tion, cardiac dysfunction and metabolic disruption in a model of FRDA hypertrophic cardio-
myopathy. Our results suggest that abnormal acetylation contributes to the pathophysiology of
heart disease in FRDA and may represent a therapeutic target for early intervention.
Methods
Mouse breeding and genotyping
This study was approved by the Institutional Animal Care and Use Committee of Indiana Uni-
versity. We used site-specific Cre-lox recombination to carry out gene deletions of interest.
We used FXNfl/fl mice to create FXN KO mice that were homozygous for heart and skeletal
muscle deletion of FXN (MCK-Cre:FXN KO), as previously published [32]. Data was collected
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from males at postnatal days 30(±5), 45(±4), and/or 65(±5). Controls were age- and sex-
matched healthy littermates (FXNfl/fl).
Echocardiography (ECHO)
Mice were anesthetized with isoflurane and placed on a warming mat with continuous moni-
toring. Transthoracic ECHO images were obtained using a VisualSonics1 2100 ultrasound
machine for small animal imaging and MS400 transducer (Fujifilm VisualSonics, Inc.,
Toronto, Canada). Functional parameters of the left ventricle and outflow tracts were mea-
sured using standard assessment techniques. Relative wall thickness (RWT) was calculated by
(2LVPWd)/LVIDd).
Cardiac catheterization
Mice were anesthetized with isoflurane and placed on a warming mat with continuous moni-
toring. Pressure-volume loops were obtained directly using a 1.2 F microconductance catheter
(Scisense, Transonic Systems Inc.), which was inserted into the right carotid artery through a
small neck incision and advanced retrograde into the left ventricle. The ADVantage pressure
volume system (Scisense, Transonic Systems Inc.) was used to acquire pressure, admittance,
phase shift, and amplitude, and real time pressure-volume data was displayed and analyzed off-
line using specialized software (Labscribe 2, iWorx, Dover, NH) [43].
Cold stress
This experiment was modeled after similar studies [38, 39]. 65 day old FXN KO (n = 5) and
FXNfl/fl (n = 6) were selected for cold exposure. Mice were deprived of food for 6 hours prior
to onset of study and for the duration of experiment. A baseline rectal temperature was taken
prior to placement in 4˚C cold room and then every 30 minutes thereafter for a total of 3
hours. A study was terminated for humane reasons if core body temperature reached 19˚C or
less.
Histology
Ventricular tissue selected for histology was fixed in 10% formalin and paraffin embedded.
Histological analysis included hematoxylin and eosin (H&E) and Masson’s Trichrome to
detect collagen as a measure of fibrosis. Collagen quantification was performed using ImageJ
(IJ1.46) to measure percent area of tissue positively stained for collagen. Three to five 20x digi-
tal micrographs were obtained from each tissue section that underwent quantification studies.
Electron microscopy (EM)
Ventricular tissue selected for electron microscopy was fixed in 2.5% glutaraldehyde and
underwent sectioning and uranyl acetate staining by the Electron Microscopy Center of Indi-
ana University School of Medicine. At least 3 separate sections from each animal strain were
selected for quantification analysis. Quantification methods were similar to methods used in
our previous work [37]. Abnormal mitochondria were identified as those containing electron-
dense inclusions, cristae loss or dissolution, and/or collapsed or condensed cristae. Mitochon-
dria and myofibril area was measured using ImageJ (IJ1.46).
Isolation of cardiac mitochondria
Mitochondrial isolation followed the method described in our previous work [28]. Freshly har-
vested hearts were submerged in ice-cold mitochondrial isolation buffer. Heart tissue was
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weighed, homogenized, and then subjected to differential centrifugation. The mitochondrial
pellet was resuspended in the appropriate buffer and used immediately for respiration assay or
western blotting, or flash frozen for later analysis.
Mitochondrial respiration
Mitochondrial isolates designated for use in respiration assays were resuspended in mitochon-
drial respiration buffer. A total of 2–3 mouse heart mitochondria were combined for each run,
with n = 4–6 pooled heart mitochondria assayed for controls and n = 8–12 pooled heart mito-
chondria assayed for FXN KO. A Clark-oxygen electrode was used for respiration assays. Glu-
tamate and malate were used as a substrate for all assays.
Antibodies and western blotting
Primary antibodies included anti-acetyl-lysine (Cell Signaling #9441), anti-SIRT3 (Cell Signal-
ing #5490), anti-SOD2 (acetyl K68) (Abcam ab137037), anti-SOD2 (Cell Signaling #13141),
anti-VDAC (Cell Signaling #4866), anti-GAPDH (Cell Signaling #5174), anti-FXN (generous
gift of Grazia Isaya, Mayo Clinic, Rochester MN), anti-LCAD (Abcam ab196655) and to the
electron transport chain complexes: anti-CI-NDUFA9 (Abcam ab14713), anti-CII-SDHB
(Abcam ab14714) and anti-CIII-UQCRFS1 (Abcam ab14746). Band intensities were measured
using ImageJ (IJ1.46). To determine correlation between acetylation and heart function, rela-
tive density of acetylation for n = 3 western blot images was normalized to day 30 controls and
averages for each group were used for correlation calculation.
Statistics
All calculations, analyses and graphs were performed using SigmaPlot (Systat Software, Inc.).
Two groups were compared using a two-tailed student’s t test for samples with equal variance.
Final data are presented as mean (±SD). Alpha was set at 0.05 and power at 0.800. A p-value of
<0.05 was considered statistically significant.
Supporting information
S1 Fig. FXN KO mice exhibit left ventricular hypertrophy and diastolic dysfunction and
transition to dilated cardiomyopathy and heart failure. FXN KO mice demonstrate cardiac
hypertrophy at ages 45 and 65 days on (a) ECHO-derived left ventricle:body mass ratio (LV:
body) and (b) left ventricular posterior wall thickness in diastole (LVPWd). Diastolic indices
in the FXN KO mice are abnormal; with increases in (c) mitral valve Doppler flow ratio (E/A)
and (d) isovolumic relaxation time (IVRT), and (e) decreased rate of left ventricle relaxation
(-dP/dt). (f) FXN KO (days 45 and 65) had significantly slower rates of contraction (+dP/dt)
and (g) maximum left ventricular power (maxPower) compared to FXNfl/fl controls. (h) FXN
KO mice demonstrate significantly depressed global contractility function compared to con-
trols for ejection fraction (EF, %) and (i) fractional shortening (FS, %). E/A = ratio of the early
(E) to late (A) ventricular filling velocity; -dP/dt = -Δintra-ventricular pressure/Δtime; +dP/
dt = +Δintra-ventricular pressure/Δtime.  = p<0.05.
(TIF)
S1 File. Dataset.
(XLSX)
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